Lipid-Lowering, Antihypertensive, and Antithrombotic Effects of Nattokinase Combined with Red Yeast Rice in Stable CAD

This Chinese RCT randomized 178 patients with stable coronary artery disease to nattokinase plus red yeast rice, nattokinase alone, red yeast rice alone, or placebo — testing whether the combination outperformed its individual components on cardiometabolic biomarkers.

The combination arm produced the greatest improvements across lipid panels, blood pressure, and antithrombotic markers including thromboxane B2 and antithrombin III. Individual component arms showed intermediate effects. The combination was well-tolerated alongside conventional cardiac medications.

The interpretation is complicated by a critical confound: red yeast rice contains monacolin K, a naturally occurring compound chemically identical to lovastatin. The “combination” result therefore partly reflects the addition of an unspecified, unstandardized statin dose. Extrapolating nattokinase’s independent contribution from a combination that includes a statin equivalent is not possible without a more carefully designed factorial trial. Clinical outcomes — heart attacks, revascularizations, death — were not measured.

We rate the evidence limited. A small biomarker RCT that cannot establish cardiovascular event benefit; red yeast rice’s monacolin K content fundamentally confounds the interpretation of nattokinase’s independent contribution.